Pregled bibliografske jedinice broj: 196331
Bone Resorption in Hyperthyroid Premenopausal Women on Thyrosuppressant Therapy
Bone Resorption in Hyperthyroid Premenopausal Women on Thyrosuppressant Therapy // Clinica chimica acta Supplement 1 / Delanghe, J. ; Wu, A.H. (ur.).
Amsterdam: Elsevier, 2005. str. S246-S246 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 196331 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Bone Resorption in Hyperthyroid Premenopausal Women on Thyrosuppressant Therapy
Autori
Milanović-Stipković, Branka ; Altabas, Velimir ; Vrkić, Nada ; Topić, Elizabeta ; Misjak, Mira
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Clinica chimica acta Supplement 1
/ Delanghe, J. ; Wu, A.H. - Amsterdam : Elsevier, 2005, S246-S246
Skup
16th IFCC - FESCC European Congress of Clinical Biochemistry and Laboratory Medicine
Mjesto i datum
Glasgow, Ujedinjeno Kraljevstvo, 08.05.2005. - 12.05.2005
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
bone resorption markers; hyperthyroid premenopausal women; thyrosuppressant therapy
Sažetak
Objective: The aim of the study was to investigate the dynamics of bone resorption markers (blood beta-crosslaps, urinary pyridinoline, deoxypyridinoline and hydroxyproline) in hyperthyroid premenopausal women treated with thiamazole. Patient and methods: The study included 45 premenopausal hyperthyroid women with no other cause of increased bone turnover. An informed consent was obtained from all study subjects. Thyroid hormones, TSH and bone resorption markers were determined at baseline, and then at 6 and 18 weeks of treatment. Statistical analysis was perforemd using Wilcoxon matched pair analysis. Results: Thyrosuppressant therapy proved successful. At 6 weeks, elevated T3 and T4 values were measured in only four women, and all women had TSH values below or at the upper reference limit. At 6 weeks, a statistically significant decrease was recorded in blood -crosslaps, urinary pyridinoline and deoxypyridinoline, and urinary hydroxyproline concentrations (p<0.01 all). At 18 weeks of therapy, all study parameters showed a decrease compared to their 6- week concentrations, however, only the deacrease in the blood beta-crosslap concentration was statistically significant (p<0.05). Conclusion: Although the rate of bone resorption was considerably slowed down by thyrosuppressant therapy, the medians of some markers were still elevated in week 18 (pyridinoline, deoxypyridinole, blood beta-crosslaps), indicating an increased rate of bone resorption in our patients. Sequential determination of any of these markers may be used to determine bone resorption in hyperthyroid patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
0134019
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE